demonstrated that GIPR agonism could reduce the risk of atherosclerosis in sensitized animal models, and human genetics revealed a correlation between hypoglycemic alleles of GIPR and reduced BMI, triglyceride levels, and heart failure incidence [51]
This study aims to investigate whether semaglutide can reduce the progression of noncalcified coronary atherosclerotic plaque volume, as measured by serial coronary computed tomography angiography (CTA), over a one-year period compared to a placebo, in individuals with diabetes
While youve hopefully made positive lifestyle changes alongside taking a GLP-1, to maintain the weight loss, youll need additional support as your appetite returns
Toxicology and Applied Pharmacology , 438 , 115910 Braun, J